Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).

Oskoui M., Day JW., Deconinck N., Mazzone ES., Nascimento A., Saito K., Vuillerot C., Baranello G., Goemans N., Kirschner J., Kostera-Pruszczyk A., Servais L., Papp G., Gorni K., Kletzl H., Martin C., McIver T., Scalco RS., Staunton H., Yeung WY., Fontoura P., Mercuri E., SUNFISH Working Group None.

DOI

10.1007/s00415-023-11658-6

Type

Journal article

Journal

J Neurol

Publication Date

18/04/2023

Permalink Original publication